Phosphoinositide-3-kinase/akt - dependent signaling is required for maintenance of $[\text{Ca}^{2+}]_i$, $I_{\text{Ca}}$, and Ca$^{2+}$ transients in HL-1 cardiomyocytes

Bridget M Graves, Thomas Simerly, Chuanfu Li, David L Williams and Robert Wondergem

Abstract
The phosphoinositide 3-kinases (PI3K/Akt) dependent signaling pathway plays an important role in cardiac function, specifically cardiac contractility. We have reported that sepsis decreases myocardial Akt activation, which correlates with cardiac dysfunction in sepsis. We also reported that preventing sepsis induced changes in myocardial Akt activation ameliorates cardiovascular dysfunction. In this study we investigated the role of PI3K/Akt on cardiomyocyte function by examining the role of PI3K/Akt-dependent signaling on $[\text{Ca}^{2+}]_i$, Ca$^{2+}$ transients and membrane Ca$^{2+}$ current, $I_{\text{Ca}}$, in cultured murine HL-1 cardiomyocytes. LY294002 (1–20 μM), a specific PI3K inhibitor, dramatically decreased HL-1 $[\text{Ca}^{2+}]_i$, Ca$^{2+}$ transients and $I_{\text{Ca}}$. We also examined the effect of PI3K isoform specific inhibitors, i.e. α (PI3-kinase α inhibitor 2; 2–8 nM); β (TGX-221; 100 nM) and γ (AS-252424; 100 nM), to determine the contribution of specific isoforms to HL-1 $[\text{Ca}^{2+}]_i$ regulation. Pharmacologic inhibition of each of the individual PI3K isoforms significantly decreased $[\text{Ca}^{2+}]_i$, and inhibited Ca$^{2+}$ transients. Triciribine (1–20 μM), which inhibits AKT downstream of the PI3K pathway, also inhibited $[\text{Ca}^{2+}]_i$, and Ca$^{2+}$ transients and $I_{\text{Ca}}$. We conclude that the PI3K/Akt pathway is required for normal maintenance of $[\text{Ca}^{2+}]_i$ in HL-1 cardiomyocytes. Thus, myocardial PI3K/Akt-PKB signaling sustains $[\text{Ca}^{2+}]_i$ required for excitation-contraction coupling in cardiomyocytes.

Keywords: Calcium, Fura-2, Phosphoinositide-3-kinase/Akt, HL-1 cardiomyocytes, Whole-cell voltage clamp, Electrophysiology

Background
The phosphoinositide 3-kinases (PI3K) are a conserved family of signal transduction enzymes that are involved in regulating cellular proliferation and survival [1,2]. The PI3Ks and the downstream serine/threonine kinase Akt (also known as protein kinase B; PKB) regulate cellular activation, inflammatory responses, chemotaxis and apoptosis [1]. We [3] and others [4] have demonstrated that activation of PI3K/Akt dependent signaling attenuates the pro-inflammatory phenotype and increases survival outcome in sepsis. We have also reported that sepsis decreases myocardial Akt activation [5], which correlates with cardiac dysfunction in sepsis. In the same report, we demonstrated that preventing sepsis-induced changes in myocardial Akt activation correlates with prevention of cardiac dysfunction [5].

PI3K/Akt/PKB may play a role in cardiomyocyte calcium regulation; however, the precise mechanisms by which this occurs have not been fully elucidated. Yano and colleagues employed a transgenic mouse model over-expressing PI3K p110α in the heart [6], which resulted in increased left ventricular pressure, increased levels of L-type Ca$^{2+}$ channels, ryanodine receptors and sarcoplasmic reticulum Ca$^{2+}$-ATPase 2a [6]. In a subsequent report, Lu et al. demonstrated that genetic ablation of PI3K p110α resulted in reduced numbers of voltage-dependent L-type Ca$^{2+}$ channels in isolated cardiomyocytes, reduced inward Ca$^{2+}$ current and a defect in contractile function [7]. Taken together the results above indicate that PI3K/Akt signaling plays a critical role in normal cardiac function and in maintaining
cardiac function in sepsis [5-7]. This signaling most likely involves regulation of cellular calcium.

We conducted the present study to determine whether direct inhibition of the PI3K, PI3K-specific isoforms or Akt-PKB signaling in HL-1 cardiomyocytes alters calcium regulation. HL-1 is a proliferating atrial myocyte cell line established from a subcutaneous tumor of AT-1 cells that, in turn, were derived from the atria of a mouse transgenic for the simian virus 40 large T antigen under control of the atrial natriuretic factor promoter [8,9]. These cells display spontaneous contractions in tissue culture, oscillations of [Ca^{2+}], and express functional L- and T-type Ca^{2+} channels [10]. HL-1 cells also express the PI3K/Akt-PKB signaling pathway, which mediates interleukin-18 induced cellular hypertrophy [11]. Herein, we report that inhibitors of PI3K/Akt-PKB decrease [Ca^{2+}], diminish Ca^{2+} transients and inhibit membrane Ca^{2+} currents, \( I_{Ca} \) in these murine cardiomyocytes. These data indicate that PI3K/Akt-PKB is required for normal cardiomyocyte calcium regulation.

**Methods**

**HL-1 cell culture**

HL-1 atrial cardiomyocytes were a gift of Dr. William Claycomb (Louisiana State University Medical Center). They were grown in 5% CO\(_2\) at 37 °C in Claycomb media (Sigma) supplemented with batch specific 10% FBS (Sigma), 100 U/ml:100 μg/ml Penicillin/Streptomycin (Invitrogen), 0.1 mM norepinephrine (Sigma) and 2 mM L-glutamine (Invitrogen). Before culturing cells, flasks were treated overnight with 0.02% Bacto© gelatin (Fisher Scientific):0.5% Fibronectin (Invitrogen). For electrophysiologic or calcium measurements cells were plated at a density of 3X10^5 cells/35-mm culture dish on tissue culture, oscillations of [Ca^{2+}], and express functional L- and T-type Ca^{2+} channels [10]. HL-1 cells also express 

**Whole-cell voltage clamp measurements**

Cells were grown for 1–2 days on 12-mm diameter glass plastic coverslips, which were transferred to an acrylic chamber (Warner Instr. Co., Hamden, CT) on the stage of an inverted microscope (Olympus IMT-2) equipped with Hoffman modulation contrast optics. Cells were superfused at room temperature with a standard external salt solution. Patch pipettes (3–6 MΩ in the bath solution) were fabricated from glass capillaries (1.1-1.2 mm ID, 0.2 mm wall thickness, non-heparinized micro-hematocrit capillary tubes; Fisher Scientific) with a Brown-Flaming horizontal micropipette puller (P-97, Sutter Instruments, Novato, CA). A micromanipulator (MO-202, Narishige, Tokyo) fixed to the microscope was used to position pipettes. The whole-cell patch configurations were obtained by standard patch clamp technique [12]. Voltage-clamp currents were measured with a patch clamp amplifier (Axopatch 200B, Axon Instruments, Foster City, CA) with the lowpass, Bessel filtering (–3 dB) set at 5 kHz. Signals from the patch clamp amplifier were fed into a computer via a digital interface (Digidata 1322A) and processed by Clampex 8 software (Axon Instruments). Ag/AgCl half-cells constituted the electrodes, and agar bridges (4% w v\(^{-1}\) in external solution) connected the reference electrodes to the bath solution. Series resistances were compensated following whole-cell access prior to recordings. Giga-ohm seals between pipettes and cell membranes were made with cells perfused with standard external solution. For \( I_{Ca} \) measurements the cells were perfused with an external solution in which an impermeable cation was substituted for Na\(^+\), and Ca\(^{2+}\) concentration was increased (below).

**Intracellular Ca\(^{2+}\) measurements**

Cells were loaded with Fura-2/AM (TefLabs, Austin, TX) by incubating them for 30 min at room temperature (22–23 °C) with a standard external salt solution containing 2-μM Fura-2/AM. Cells were then washed with the external salt solution and incubated at 37 °C with 5% CO\(_2\) for 30 min in the supplemented Claycomb media. The coverslip was transferred to an acrylic chamber (Warner Instr. Co., Hamden, CT) on the microscope stage and washed with the external salt solution for 5 minutes before measurements. Temperature was maintained throughout measurements at 37 °C by a stage/inline temperature controller (Warner Instr. Co., Hamden, CT). Fluorescence was measured with an imaging system consisting of a xenon fiber optic light source (Perkin-Elmer, Waltham, MA), a filter wheel and a Basler A311F VGA Camera connected to an Olympus IX71 inverted fluorescence microscope. The filter wheel and data acquisition were controlled by the InCyte2 software (v. 5.29; Intracellular Imaging, Cincinnati, OH). [Ca\(^{2+}\)] was determined by interpolation from a standard curve generated by Ca\(^{2+}\) calibration buffer kit #2 (Molecular Probes @ Life Technologies, Grand Island, NY) and Fura-2/K\(_{so}-\)salt. After correction for the individual background fluorescence, the ratio of the fluorescence at both excitation wavelengths (F340/F380) was monitored simultaneously in 30–40 cells, identified by their fluorescence within a single view field. Images were collected every 3.3 s. Each slide was perfused with standard external salt solution for 6 min for control measurements, followed by 10 min with the experimental solution. At 16 min, the slide was washed with standard external salt solution for 5 min, and at 21 min data collection was stopped. Data was then exported to MS Excel and graphed using Origin 7.0 (OriginLab Corp., Northampton, MA) and Sigmaplot 11.0 (Systat Software, Inc., Chicago, IL). For statistical analyses, average [Ca\(^{2+}\)],
from 25–40 cells within a microscopic field were obtained during the control period of 1–5 min from each of 5 separate HL-1 cell preparations. These averages were then compiled to obtain average control values (n = 5), and comparisons were made on data collected similarly from the same microscopic fields 15 minutes after experimental additions. Statistical differences were calculated similarly from the same microscopic fields (n = 5), and comparisons were made on data collected on each of 5 separate HL-1 cell preparations. These solution constituents were obtained from SigmaAldrich, St. Louis, MO.

LY 294002 was obtained from Alomone Labs, LTD, Jerusalem, Israel. The PI3 kinase isoform inhibitors: PI3-kinase α inhibitor 2, TGX-221 β inhibitor, AS-252424 γ isoform inhibitor; and the AKT inhibitor, Triciribine were obtained from Cayman Chemical, Ann Arbor, MI. The dosages selected for the various inhibitors were based on the literature and the manufacturer’s instructions. All inhibitors were dissolved in DMSO in stock solutions and then diluted to final concentration. The highest final concentration of DMSO by this approach was 0.24% DMSO.

Results
Pharmacologic inhibition of PI3K significantly reduces [Ca<sup>2+</sup>]<sub>i</sub>, and Ca<sup>2+</sup> transients in HL-1 cardiomyocytes

Action potentials and corresponding spontaneous transients in intracellular Ca<sup>2+</sup>, [Ca<sup>2+</sup>]<sub>i</sub>, occur in approximately 40% of non-confluent immortalized mouse HL-1 cardiomyocytes [13,14]. Synchronous Ca<sup>2+</sup> transients in three such cells are shown in Figure 1A. Perfusing the cells with LY 294002 (20 μM), a potent inhibitor of phosphoinositide-3-kinases (PI3Ks), inhibited Ca<sup>2+</sup> transients within 2 minutes, and this effect was partially reversed on washout. When all cells within a microscopic field (n = 37), i.e. those showing Ca<sup>2+</sup> transients and those without transients, were included in the computation of mean [Ca<sup>2+</sup>]<sub>i</sub>, the Ca<sup>2+</sup> transients again were evident, but the averaging reduced their magnitude, Figure 1B. LY 294002 again abolished the Ca<sup>2+</sup> transients and diminished total [Ca<sup>2+</sup>]<sub>i</sub>, Figure 1B. Washout restored total [Ca<sup>2+</sup>]<sub>i</sub>, but the Ca<sup>2+</sup> transients were no longer apparent, except for partial restoration in 3 cells out of the 10 of 37 cells showing Ca<sup>2+</sup> transients (results not shown). LY 294002 at 1 μM also inhibited Ca<sup>2+</sup> transients with some restoration on washout, Figure 1C. LY 294002 at 1 μM also significantly reduced total [Ca<sup>2+</sup>]<sub>i</sub>, Table 1, with modest but insignificant reversal on washout within 5 minutes, Figure 1D. Surprisingly, 10-μM LY 294002 inhibition was insignificant. We attribute this inconsistency to the variation in differentiated phenotype among the population of HL-1 cells within a microscopic field. The dynamic response of [Ca<sup>2+</sup>]<sub>i</sub>, depends on Ca<sup>2+</sup> oscillations [14], which in turn depend on the I<sub>Ca</sub>, whose phenotype varies in these cells [13].

Inhibition of PI3K isoforms and akt significantly reduces [Ca<sup>2+</sup>]<sub>i</sub>, I<sub>Ca</sub> and Ca<sup>2+</sup> transients in HL-1 cardiomyocytes

Considering that LY 294002 is a broad spectrum inhibitor of PI3Ks and binds to various targets [15], we performed measurements to determine whether inhibitors of specific PI3K isoforms (i.e. α, β and γ) have similar effects on Ca<sup>2+</sup> transients and total [Ca<sup>2+</sup>]<sub>i</sub>. PI3-kinase α inhibitor 2 (2 nM) abolished Ca<sup>2+</sup> transients in HL-1 cells within 3 to 4 min, Figure 2A, with no reversal on washout. It also significantly reduced total HL-1 [Ca<sup>2+</sup>]<sub>i</sub>, Table 2 and Figure 2B. Identical effects were obtained for the PI3K β inhibitor (TGX-221, 100 nM), Figures 3A & 3B and Table 3, as well as for the PI3K γ inhibitor (AS-252424, 100 nM), Figures 4A & 4B and Table 3. A major downstream target of PI3K is Akt/PKB [16]. Therefore, we pharmacologically inhibited Akt in order to determine if the effect of PI3K on myocardial [Ca<sup>2+</sup>]<sub>i</sub>, is mediated via Akt. Triciribine (10 μM), a specific inhibitor of Akt, also inhibited Ca<sup>2+</sup> transients in HL-1 cells with modest reversal of this inhibition on washout, Figure 5A. Triciribine also significantly decreased HL-1 cell total [Ca<sup>2+</sup>]<sub>i</sub>, and this did not reverse on washout, Table 4 and Figure 5B. DMSO (0.24%), the diluent used for these inhibitors, had no effect on [Ca<sup>2+</sup>]<sub>i</sub> = 125.3 ± 7.2 nM compared with Control [Ca<sup>2+</sup>]<sub>i</sub> = 131.6 ± 7.9 nM (p = 0.18; n = 5).

Pharmacologic inhibition of PI3K and Akt significantly reduces I<sub>Ca</sub>

As an initial step to determine whether the effects by inhibitors of PI3Ks and of Akt on Ca<sup>2+</sup> transients and total [Ca<sup>2+</sup>]<sub>i</sub>, resulted from inhibition of membrane Ca<sup>2+</sup> channels, we determined the effect of LY 294002 and triciribine on membrane Ca<sup>2+</sup> currents in HL-1 cells. For these measurements the pipette-membrane gigahm seal and whole-cell access were obtained with cells perfused with standard external solution. Once achieved, the external solution was exchanged to one in which Na<sup>+</sup> was substituted with NMDG<sup>+</sup> and [Ca<sup>2+</sup>]<sub>i</sub> increased from 1.5 to 5 mM. Following 5-min equilibration, voltage clamp step protocols were performed to generate current–voltage

Solutions and chemicals

Standard external salt solution contained (mM): NaCl 150, KCl 6, MgCl<sub>2</sub> 1, CaCl<sub>2</sub> 1.5, N-2-Hydroxyethylpiperazine -N’-2-ethanesulfonic acid (HEPES) 10, glucose 10 (pH adjusted to 7.41 with NaOH). Pipette solution contained (mM): potassium aspartate 120, Na<sub>2</sub>GTP 0.4, Na<sub>2</sub>ATP 5, MgCl<sub>2</sub> 1, EGTA 5, CaCl<sub>2</sub> 0.1, HEPES 10 (pH adjusted to 7.2 with KOH). For whole-cell voltage clamp measurements of membrane Ca<sup>2+</sup> currents external NaCl was substituted with (mM) n-methyl-D-glucamine chloride (NMDG<sup>+</sup>) 150, and CaCl<sub>2</sub> was increased to 5 to maximize Ca<sup>2+</sup> current. All solution constituents were obtained from SigmaAldrich, St. Louis, MO.

Table 4 and Figure 5B. DMSO (0.24%), the diluent used for these inhibitors, had no effect on [Ca<sup>2+</sup>]<sub>i</sub> = 125.3 ± 7.2 nM compared with Control [Ca<sup>2+</sup>]<sub>i</sub> = 131.6 ± 7.9 nM (p = 0.18; n = 5).

Pharmacologic inhibition of PI3K and Akt significantly reduces I<sub>Ca</sub>

As an initial step to determine whether the effects by inhibitors of PI3Ks and of Akt on Ca<sup>2+</sup> transients and total [Ca<sup>2+</sup>]<sub>i</sub>, resulted from inhibition of membrane Ca<sup>2+</sup> channels, we determined the effect of LY 294002 and triciribine on membrane Ca<sup>2+</sup> currents in HL-1 cells. For these measurements the pipette-membrane gigahm seal and whole-cell access were obtained with cells perfused with standard external solution. Once achieved, the external solution was exchanged to one in which Na<sup>+</sup> was substituted with NMDG<sup>+</sup> and [Ca<sup>2+</sup>]<sub>i</sub> increased from 1.5 to 5 mM. Following 5-min equilibration, voltage clamp step protocols were performed to generate current–voltage
plots (I/V plots, Figure 6) obtained at maximal inward current, Figure 6A inset, under control conditions and following five minutes of an inhibitor of either PI3Ks or Akt. The holding potential throughout these measurements was −50 mV. Depolarizing voltage steps activated inward current at ~−40 mV, with maximal inward current occurring with depolarizations ranging from −10 to 20 mV, Figures 6A and 6B. The voltage-activated inward currents were inhibited completely by perfusing the cells for 5 min with either LY 294002 (10 μM), Figure 6A, or with triciribine (10 μM), Figure 6B. Inward currents also were completely abolished by perfusing the cells with external solution in which NMDG+ substituted for both Na+ and Ca2+ (results not shown).

Table 1 Effect of phosphoinositide-3-kinase inhibitor LY 294002 on intracellular Ca2+ concentration recorded 15 minutes after addition of respective inhibitors

| Agent (Concentration) | Control [Ca2+]i (nM) | Inhibitor (15 min) [Ca2+]i (nM) | P value for difference |
|-----------------------|-----------------------|--------------------------|----------------------|
| LY 294002 (1 μM) PI3K | 141.6 ± 10.1 | 124.9 ± 6.9 | <0.03 |
| PI3K LY 294002 (10 μM) | 160.6 ± 24.4 | 134.8 ± 12.0 | =0.29 |
| PI3K LY 294002 (20 μM) | 132.6 ± 5.2 | 117.1 ± 6.1 | <0.003 |

Mean ± SEM (n = 3 or 5 experiments each, with each experiment comprising the average [Ca2+] of 25 to 40 cells).
Discussion

These findings show that PI3K/Akt-PKB signaling pathways play a significant role in regulating intracellular Ca\(^{2+}\) in HL-1 cells, which constitute a murine-derived, immortalized cell line with phenotypes like those of adult cardiomyocytes [8,9]. We found that LY 294002, a specific inhibitor of PI3K, as well as specific inhibitors of each of the PI3K isoforms, i.e., α, β and γ catalytic PI3K subunits, and an inhibitor of Akt/PKB, significantly decreased [Ca\(^{2+}\)]\(_i\) and abolished Ca\(^{2+}\) transients or oscillations. Moreover, inhibition of PI3K/Akt-PKB signaling pathways abolished inward Ca\(^{2+}\) current in the HL-1 cells, which likely results from L-type Ca\(^{2+}\) channels in HL-1 cells.

Taken together we conclude that the PI3K/Akt-PKB signaling pathway plays a role in sustaining the voltage-activated Ca\(^{2+}\) current contributing to the HL-1 cell action potential. Catalucci et al. [17] have shown that Akt-dependent phosphorylation of Ca,β2, the chaperone of the L-type Ca\(^{2+}\) channel pore-forming subunit, Ca,α1, antagonizes Ca,α1 degradation and, as such, stabilizes the functional channel in the plasma membrane. Inward Ca\(^{2+}\) currents from action potential, via voltage-activated membrane Ca\(^{2+}\) channels, induce Ca\(^{2+}\) release from the sarcoplasmic reticulum [18,19], which accounts for excitation-contraction coupling in cardiomyocytes [20].

We observed a two- to five-minute delay for various PI3K/Akt-PKB inhibitors to reduce Ca\(^{2+}\) transients, [Ca\(^{2+}\)]\(_i\), and I\(_{Ca}\). This is consistent with a time course for the manifestation of inhibition of an enzymatic signaling cascade. We conclude also that this delay is inconsistent with a direct inhibition of membrane Ca\(^{2+}\) channels by the various inhibitors, which most likely would occur faster. The marked reduction of I\(_{Ca}\) by PI3K/Akt-PKB inhibitors likely results from diminution of L-type I\(_{Ca}\). We cannot rule out involvement of T-type I\(_{Ca}\) since both are expressed in HL-1 cells [10]. However, based upon our holding potential of -50 mV compared with the more electronegative activating voltages for T-type Ca\(^{2+}\) channels [10] and the relatively extended time course of our I\(_{Ca}\), the effects measured here

Table 2 Effect of phosphoinositide-3-kinase α inhibitor on intracellular Ca\(^{2+}\) concentration recorded 15 minutes after addition of respective inhibitors

| Agent (Concentration) Target | Control [Ca\(^{2+}\)]\(_i\) (nM) | Inhibitor (15 min) [Ca\(^{2+}\)]\(_i\) (nM) | P value for difference |
|-----------------------------|---------------------------------|----------------------------------------|------------------------|
| PI3K α inhibitor 2 (2 nM) α | 136.4 ± 8.6                     | 118.3 ± 5.9                            | <0.02                  |
| PI3K α inhibitor 2 (4 nM) α | 114.9 ± 4.3                     | 102.1 ± 2.5                            | <0.01                  |
| PI3K α inhibitor 2 (8 nM) α | 131.7 ± 9.0                     | 110.5 ± 4.7                            | =0.06                  |

Mean ± SEM (n = 5 experiments each, with each experiment comprising the average [Ca\(^{2+}\)] of 25 to 40 cells).
are likely those of L-type $I_{\text{Ca}}$. Finally, we conclude that the large outward currents seen in the I/V plots at potentials $>30$ mV result from $K^+$ currents whose magnitude we have found to vary considerably among HL-1 cells in non-confluent culture (Wondergem, unpublished observations).

These findings also have implications for our understanding of the role of PI3K/Akt-PKB signaling in disease. As noted above, we have reported that sepsis results in decreased activation of the PI3K/Akt pathway in the myocardium [5]. We have also discovered that constitutive up regulation of PI3K p110α in the myocardium prevents sepsis induced cardiac dysfunction and improves survival outcome in septic mice (Li, Williams and colleagues, unpublished observations). Although PI3K/Akt-PKB inhibition in septic mice undoubtedly leads to increased cytokine production in these animals [3], the present findings also indicate that PI3K/Akt-PKB inhibition directly decreases availability of $Ca^{2+}$ in the mouse cardiomyocytes. Consistent with this conclusion are the reports that ventricular myocytes obtained from endotoxemic guinea-pigs [21] and septic pigs [22] show marked reduction in L-type calcium current; whereas, Akt/PKB overexpression in transgenic mice results in cardiac hypertrophy, increased amplitude of $Ca^{2+}$ transients and enhanced L-type membrane $Ca^{2+}$ currents [23]. Lipopolysaccharide treatment of rats also leads to arrhythmogenesis attributable to reduced mRNA levels encoding for L-type $Ca^{2+}$ subunits [24]. We reported that LPS directly reduces $Ca^{2+}$ transients in HL-1 cells; however, LPS has no direct effect on L-type $Ca^{2+}$ currents in these cells, acting instead to reduce the funny current, $I_{\text{f}}$ [14] as also shown by others [25]. Thus, to whatever extent sepsis reduces cardiomyocyte $[Ca^{2+}]_i$ and $Ca^{2+}$ transients by inhibition of PI3K/Akt-PKB, elevated cytokines most likely effect these reductions and not LPS directly. On the other hand, the present findings suggest that the amelioration of sepsis and endotoxemia by preconditioning [26] or ischemia [27] may result from upregulation of the PK3/Akt-PKB signaling pathways [3,28-32], which directly increases $[Ca^{2+}]_i$ available for excitation-contraction coupling in cardiomyocytes.

All PI3K/Akt-PKB inhibitors used in these experiments inhibited $Ca^{2+}$ transients and significantly decreased $[Ca^{2+}]_i$; however, we cannot attribute the importance of one inhibitor over and against that of the others. Similar inhibition $Ca^{2+}$ transients and $[Ca^{2+}]_i$ by LY294002 at either 20- or 1-$\mu$M rules out toxicity by the drug. Still, there is considerable variability among HL-1 cells regarding the

| Table 3 Effect of phosphoinositide-3-kinases β and γ inhibitors on intracellular $Ca^{2+}$ concentration recorded 15 minutes after addition of respective inhibitors |
|---|---|---|---|
| Agent (Concentration) | Control | Inhibitor (15 min) | P value for difference |
| Target | $[Ca^{2+}]_i$ (nM) | $[Ca^{2+}]_i$ (nM) | |
| TTX-221 (100 nM) | 105.5 ± 5.0 | 96.6 ± 4.8 | <0.03 |
| β | | | |
| AS-252424 (100 nM) | 121.8 ± 4.3 | 111.9 ± 6.0 | <0.03 |

Mean ± SEM (n = 5 experiments each, with each experiment comprising the average $[Ca^{2+}]$ of 25 to 40 cells).
Figure 4 Pharmacologic inhibition of phosphoinositide-3-kinase (PI3K) isoform γ decreases Ca$^{2+}$, [Ca$^{2+}$]$_i$, in HL-1 cell mouse cardiomyocytes. A. Effect of AS-252424 (100 nM) on [Ca$^{2+}$]$_i$ oscillations in five representative HL-1 cells. Time base applies to all traces. B. Effect of AS-252424 (100 nM) on average [Ca$^{2+}$]$_i$ in cells displaying oscillating and non-oscillating [Ca$^{2+}$]$_i$ (mean ± SEM; n = 5, each an average of 25 to 40 cells as shown in A).

Figure 5 Akt-PKB inhibition with triciribine decreases Ca$^{2+}$, [Ca$^{2+}$]$_i$, in HL-1 cell mouse cardiomyocytes. A. Effect of triciribine (10 μM) on [Ca$^{2+}$]$_i$ oscillations in five representative HL-1 cells. Time base applies to all traces. B. Effect of triciribine (10 μM) on average [Ca$^{2+}$]$_i$ in cells displaying oscillating and non-oscillating [Ca$^{2+}$]$_i$ (mean ± SEM; n = 5, each an average of 25 to 40 cells as shown in A).

Table 4 Effect of Akt-PKB inhibitor on intracellular Ca$^{2+}$ concentration recorded 15 minutes after addition of respective inhibitors

| Agent (Concentration) | Control | Inhibitor (15 min) | P value for difference |
|-----------------------|---------|--------------------|------------------------|
|                       | [Ca$^{2+}$]$_i$ (nM) | [Ca$^{2+}$]$_i$ (nM) |                        |
| Triciribine (1 μM)    | 177.4 ± 5.2 | 157.7 ± 1.9 | <0.05                  |
| Akt-PKB               | 125.7 ± 4.4 | 104.6 ± 4.8 | <0.03                  |
| Triciribine (10 μM)   | 216.8 ± 4.1 | 203.9 ± 1.4 | =0.13                  |

Mean ± SEM (n = 3 or 5 experiments each, with each experiment comprising the average [Ca$^{2+}$] of 25 to 40 cells).
amplitude and rate of Ca$^{2+}$ transients, as well as [Ca$^{2+}$]$_i$. We attribute this to variation in differentiated phenotype of HL-1 cells 1–2 days after passage. While paired comparisons of the results between control and experimental conditions clearly demonstrate effects of these inhibitors, the variations among HL-1 cells in the strength of myocyte function in the presence and absence of disease.

Conclusions

In sum, we have found that inhibitors of the PI3K/Akt signaling cascade decrease total [Ca$^{2+}$]$_i$, intracellular Ca$^{2+}$ transients and membrane $I_{Ca}$ in a murine, immortalized cardiomycocyte cell line, HL-1 cells. These data demonstrate that PI3K/Akt dependent signaling is required for normal Ca$^{2+}$ metabolism in murine cardiomyocytes. This extends our knowledge of the role of PI3K/Akt signaling in cardiovascular homeostasis. We conclude that maintaining myocardial PI3K/Akt signaling is essential for cardiomyocyte function in the presence and absence of disease.

Abbreviations

PI3K: Phosphoinositide-3-kinase; Akt: Protein kinase B; HL-1 cells: Proliferating atrial myocytes established from a tumor of AT-1 cells that, in turn, were derived from the atria of a mouse transgenic for the simian virus 40 large T antigen under control of the atrial natriuretic factor promoter; [Ca$^{2+}$]$_i$: Intracellular calcium ion; ATP: Adenosine triphosphate; GTP: Guanosine triphosphate; HEPES: N-2-Hydroxyethylpiperazine-N$'$_2-ethanesulfonic acid; $I_{Ca}$: Membrane calcium current; FBS: Fetal bovine serum; EGTA: Ethylene glycol-bis (2-aminoethyl ether)-$N,N,N',N'$-tetraacetic acid; NMDG: n-methyl-D-glucamine; $I/V$: Current–voltage; L-type: Long-lasting; T-type: Transient; $f$: Furry current.

Competing interests

The authors declare that they have no competing interests.

Acknowledgements

This work was supported in part by NIH HL071837 to C. Li, NIH GM53552 to D.L. Williams and NIH GM083016 to C. Li and D.L. Williams.

Author details

1Departments of Surgery, James H. Quillen College of Medicine, East Tennessee State University, P.O. Box 70,576, Johnson City, TN 37614-1708, USA. 2Departments of Biomedical Science, James H. Quillen College of Medicine, East Tennessee State University, Johnson City, TN 37614, USA. 3Department of Physiology/Biomedical Science, James H. Quillen College of Medicine, East Tennessee State University, P.O. Box 70,576, Johnson City, TN 37614-1708, USA.

Authors’ contributions

BMG wrote the first draft of the manuscript; performed all Ca$^{2+}$ measurements and analyzed data; TS analyzed data and contributed to writing and editing of the manuscript; CL contributed to the experimental design and writing of the manuscript; DLW designed experiments and wrote and revised the manuscript; RW performed all electrophysiology and wrote and edited the manuscript. All authors read and approved the final manuscript.

Received: 19 March 2012 Accepted: 20 June 2012 Published: 20 June 2012

References

1. Cantley LC, Cantley LC. The phosphoinositide 3-kinase pathway. Science (New York, NY 2002, 296:1655–1657.
2. Fruman DA, Cantley LC: Phosphoinositide 3-kinase in immunological systems. Semin Immunol 2002; 14:7–18.
3. Williams DL, Li C, Ha T, Ozment-Skelton T, Kalbfleisch JH, Preiszner J, Brooks L, Breuel K, Schweitzer JB: Modulation of the phosphoinositide 3-kinase pathway alters innate resistance to polymicrobial sepsis. J Immunol 2004; 172:440–446.
4. Bommhardt U, Chang KC, Swanson PE, Wagner TH, Tinsley KW, Karl IE, Hotchkiss RS: Akt decreases lymphocyte apoptosis and improves survival in sepsis. J Immunol 2004; 172:7583–7591.
5. Ha T, Hua F, Grant D, Xia Y, Ma J, Gao X, Kelley J, Williams DL, Kalbfleisch J, Bowder IW, et al: Glucan phosphate attenuates cardiac dysfunction and inhibits cardiac MiF expression and apoptosis in septic mice. Am J Physiol 2006; 291:H1910–H1918.
6. Yano N, Tseng A, Zhao TC, Robbins J,Padbury JF, Tseng YT: Temporally controlled overexpression of cardiac-specific PI3Kalpha induces enhanced myocardial contractility—a new transgenic model. Am J Physiol Heart Circ Physiol 2008; 295:H1690–H1694.
7. Lu Z, Jiang YP, Wang W, Xu JH, Mathias RT, Entcheva E, Ballou LM, Cohen I, Lin RZ: Loss of cardiac phosphoinositide 3-kinase p110 alpha results in contractile dysfunction. Circulation 2009; 120:318–325.
8. Claycomb WC, Lanson NA Jr, Stallworth BS, Egeland DB, Delcarpio JB, Bahnishi A, Izso NJ Jr: HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. Proc Natl Acad Sci USA 1998; 95:2979–2984.
9. White SM, Constantin PE, Claycomb WC: Cardiac physiology at the cellular level: use of cultured HL-1 cardiomyocytes for studies of cardiac muscle cell structure and function. Am J Physiol Heart Circ Physiol 2004; 286:H823–H829.
10. Xia M, Salata JJ, Figueroa DJ, Lawlor AM, Liang HA, Liu Y, Connolly TM: Functional expression of L- and T-type Ca2+ channels in murine HL-1 cells. J Mol Cell Cardiol 2004; 36:111–119.
11. Choudhurie A, Murri M, Claycomb WC, Mestral R, Nemir M, Interleukin-18: a pro-hypotrophic cytokine that acts through a phosphatidylinositol 3-kinase-phosphoinositide-dependent kinase-1-Akt-GATA4 signaling pathway in cardiomyocytes. J Biol Chem 2005; 280:4553–4567.
12. Hamill OP, Marty A, Neher E, Sakmann B, Sigworth FJ: Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch 1981; 391:85–100.
13. Santani L, Bochet P, Cerbai E, Mugelli A, Fischmeister R: Functional expression of the hyperpolarization-activated, non-selective cation current I(f) in immortalized HL-1 cardiomyocytes. J Physiol 2002; 545:81–92.
14. Wondergem R, Graves BM, Ozment-Skelton TR, Li C, Williams DL: Lipopolysaccharides directly decrease Ca2+ oscillations and the hyperpolarization-activated nonselective cation current I(f) in immortalized HL-1 cardiomyocytes. Am J Physiol Cell Physiol 2010; 299:C665–C671.
15. Gharsil SJ, Zveibil MJ, Shuttlsworth SJ, Hancock T, Naghiri N, Timms JF, Waterfield MD: Exploring the specificity of the PI3K family inhibitor LY294002. Biochem J 2007; 404:15–21.
16. Dugouard C, Gervais M, Corvol P, Monnot C: A new transgenic model. Am J Physiol 1998, 321:2333–2338.
17. Catalucci D, Zang DH, DeSantangelo J, Almond F, Baraga G, Chemin J, Bonci D, Pichot E, Rusconi F, Dalton ND, et al: Akt regulates L-type Ca2+ channel activity by modulating Cavalpha1 protein stability. J Cell Bio 2009; 184:923–933.
18. Beri DM, Perez-Reyes E: Ca channels in cardiac myocytes: structure and function in Ca influx and intracellular Ca release. Cardiovasc Res 1990; 24:339–360.
19. Wang SQ, Song LS, Lakatta EG, Cheng H: Ca2+ signalling between single L-type Ca2+ channels and ryanodine receptors in heart cells. Nature 2001; 410:592–596.
20. Biers DM: Cardiac excitation-contraction coupling. Nature 2002; 415:198–205.
21. Zhong J, Hwang TC, Adams HR, Rubin LJ: Reduced L-type calcium current in ventricular myocytes from endotoxemic guinea pigs. Am J Physiol 1997; 273:H2312–H2324.
22. Stengel B, Bartek F, Sykora R, Chvojka J, Benes J, Krouczyk A, Novak I, Sviglerova J, Kuncova J, Matejovic M: Reduced L-type calcium current in ventricular myocytes from pigs with hyperdynamic septic shock. Crit Care Med 2010; 38:579–587.
23. Kim YK, Kim SJ, Yotani A, Huang Y, Castelli G, Vatner DE, Liu J, Zhang Q, Diaz G, Zieba R, et al: Mechanism of enhanced cardiac function in mice with hypertrophy induced by overexpressed Akt. J Biol Chem 2003; 278:47622–47628.
24. Okazaki R, Nossaci Y, Miyashita Y, Hiyama Y, Kobayashi Y, Kato T, Mizuno K, Sekiguchi A, Yasumita T: Lipopolysaccharide induces atrial arrhythmogenesis via down-regulation of L-Type Ca2+ channel genes in rats. Int J Heart 2009; 50:353–363.
25. Zom-Pauly K, Pelzmann B, Lang P, Machler H, Schmidt H, Ebelt H, Wederkan K, Koidl B, Muller-Werdan U: Endotolxin impairs the human pacemaker current If. Shock (Augusta, Ga 2007; 28:655–661.
26. Muny CE, Jennings RB, Reiner KA: Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986, 74: 1124–1136
27. Brown JM, Grosso MA, Terada LS, Whitman GJ, Banerjee A, White CW, Harken AH, Rippe JE: Endotolxin pretreatment induces endogenous myocardial catalse activity and decreases ischemia-reperfusion injury of isolated rat hearts. Proc Natl Acad Sci U S A 1989; 86:2516–2520.
28. Fukao T, Koyasu S: PI3K and negative regulation of TLR signaling. Trends Immunol 2003, 24:358–363.
29. Guha M, MacKinn P: The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells. J Biol Chem 2002; 277:32124–32132.
30. Ha T, Hu Y, Liu L, Lu C, McMullen JR, Kelley J, Koo RL, Williams DL, Gao X, Li C: TLR2 ligands induce cardioprotection against ischemia/reperfusion injury through a PI3K/Akt-dependent mechanism. Cardiovasc Res 2010; 87:694–703.
31. Li C, Ha T, Kelley J, Gao X, Qiu Y, Kao RL, Browder W, Williams DL: Modulating Toll-like receptor mediated signaling by (1–>3)-beta-D-glucan rapidly induces cardioprotection. Cardiovasc Res 2004; 61:538–547.
32. Zhou H, Qian J, Li C, Li J, Zhang X, Ding Z, Gao X, Han Z, Cheng Y, Liu L: Attenuation of cardiac dysfunction by HSP12B in endotolxin-induced sepsis in mice through a PI3K-dependent mechanism. Cardiovasc Res 2011; 89:109–118.
33. Toyoda F, Ding WG, Zankov DP, Omatu-Kanbe M, Isono T, Horie M, Matsuura H: Characterization of the rapidly activating delayed rectifier potassium current, I(Kr), in HL-1 mouse atrial myocytes. J Membr Biol 2010, 235:73–87.